Trial Profile

A Phase 2, open-label study to assess copper and molybdenum balance in participants with Wilson disease treated with ALXN1840

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tiomolibdate choline (Primary)
Indications Hepatolenticular degeneration
Focus Therapeutic Use
Sponsors Alexion AstraZeneca Rare Disease

Most Recent Events

20 May 2026 Results presented at Monopar Therapeutics Inc. media release.
19 May 2026 According to Monopar Therapeutics Inc. media release, data from this trial has published a peer-review journal Hepatology Communications.
13 Nov 2025 According to Monopar Therapeutics media release,On September 14-15, 2025, the Company presented new data on the long-term neurological efficacy and safety of ALXN1840 (tiomolybdate choline) at the 150th American Neurological Association (ANA) Annual Meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com